Larazotide Acetate vs 5-Amino-1MQ
Side-by-side comparison of key properties, dosing, and research.
Recovery & Repair
Larazotide AcetateFat Loss & Metabolic
5-Amino-1MQ- Summary
- Larazotide acetate is an 8-amino acid peptide (Gly-Gly-Val-Leu-Val-Gln-Pro-Gly) derived from Zonula Occludens Toxin (ZOT) of Vibrio cholerae. It paradoxically acts as a ZOT antagonist to close tight junctions and reduce intestinal permeability ('leaky gut'). It is the most advanced clinical compound targeting gut permeability directly.
- 5-Amino-1MQ is a small-molecule NNMT (Nicotinamide N-methyltransferase) inhibitor that raises intracellular NAD+ levels and promotes fat burning. It is notable for targeting adipose tissue directly, reducing fat cell size and number while increasing metabolic rate.
- Half-Life
- Local gut action; minimal systemic exposure
- Estimated 4–8 hours
- Admin Route
- Oral
- Oral
- Research
- —
- —
- Typical Dose
- 0.5-2 mg
- 50–100 mg
- Frequency
- 3x daily
- Once to twice daily
- Key Benefits
- Directly reduces intestinal tight junction permeability
- Clinical efficacy in celiac disease (Phase 3 trials)
- Reduces systemic inflammation from gut permeability
- Targets root cause of leaky gut (Zonulin pathway)
- Local gut action without systemic absorption
- Potential application in IBS, IBD, autoimmune conditions
- Raises intracellular NAD+ levels
- Directly targets adipose tissue for fat reduction
- Reduces fat cell size and differentiation
- Increases basal metabolic rate
- SIRT1 activation for metabolic regulation
- No stimulant cardiovascular side effects
- Synergistic with intermittent fasting and caloric restriction
- May have anti-aging metabolic benefits
- Side Effects
- Headache (mild, dose-dependent)
- Nausea (rare)
- Well-tolerated overall in clinical trials
- Generally well-tolerated in available studies
- Mild GI discomfort (rare)
- Limited long-term human data
- Stacks With
- —
- —